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Hepatitis C virus (HCV) infection is a major cause of end-stage
liver disease and hepatocellular carcinoma. There have been
rapid advances in HCV treatment with the development of oral
direct-acting antivirals (DAAs). Studies have shown sustained
virological response rates above 90% with combinations of DAAs,
including patients with compensated cirrhosis. Thus far, signifi-
cant drug toxicity has not been seen with these agents, but there
is limited experience of using DAAs in decompensated HCV cir-
rhosis. This report describes the first experience of serious
drug-induced hepatotoxicity with the new DAAs. The mechanism
underlying these drug reactions is currently unknown. Few
patients with decompensated cirrhosis have been treated with
DAAs, so the exact pharmacokinetics in this population have
not been characterised. In both cases presented here, patients
were taking or had recently taken other drugs. It is possible that
an unknown interaction or reaction to the drug combination
caused the hepatotoxicity. Although the association with the
DAAs is not proven these cases indicate that patients with
advanced liver disease need close monitoring while on DAA ther-
apy and if there is a significant unexplained deterioration in liver
function the DAAs should be discontinued.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Journal of Hepatology 20
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Hepatitis C virus (HCV) infection is a major cause of end-stage
liver disease and hepatocellular carcinoma (HCC). There have
been rapid advances in treatment with the development of oral
direct-acting antivirals (DAAs) such as sofosbuvir (NS5B nucleo-
tide analogue), daclatasvir and ledipasvir (NS5A inhibitors).
Studies have shown that the combination of sofosbuvir with
ledipasvir or daclatasvir ± ribavirin for 12 or 24 weeks achieves
sustained virological response rates above 90% including patients
with compensated cirrhosis [1,2]. There is limited experience of
using DAAs in decompensated HCV cirrhosis but initial studies
with sofosbuvir/ledipasvir show good rates of sustained virological
response and few adverse events [3,4]. Thus far, significant drug
toxicity has not been seen with these agents. We report two
cases of significant hepatotoxicity related to treatment with
sofosbuvir and NS5A inhibitors as part of the English early
access program. In this program, patients with decompensated
cirrhosis due to hepatitis C (defined as Child-Pugh score 7 or current/
previous decompensation with ascites, variceal bleed or
encephalopathy) received 12 weeks of treatment with sofosbuvir,
ribavirin and ledipasvir or daclatasvir. The sofosbuvir was funded
by the National Health Service (NHS) and the ledipasvir or
daclatasvir was provided compassionately from Gilead and
Bristol-Myers Squibb, respectively, as these drugs were unlicensed
at that time. Informed consent was obtained from all patients. In
total, approximately 500 patients were treated in this program
nationally; 30 in Newcastle and 56 in Leeds.Case studies
Case 1
A 74-year-old male with haemophilia A, genotype 1a HCV and
HIV co-infection with decompensated cirrhosis (Child-Pugh score
9, MELD 16) had previously suffered hepatic decompensation
with ascites during treatment with pegylated-interferon-a and
ribavirin in 2009. He had oesophageal varices and ascites
(controlled with spironolactone 100 mg daily). There was no history
of alcohol use. His HIV was well-controlled (CD4 T-lymphocytes16 vol. 64 j 234–238
Table 1. Routine blood results for case 1 during a period of hepatic decompensation.
Number of days post anti-HCV therapy Bilirubin 
(μmol/L, 0-21)
Albumin 
(g/L, 35-50)
INR ALT
(IU/L, 0-40)
ALP
(IU/L, 30-150)
Creatinine 
(μmol/L, 75-140)
Haemoglobin 
(g/L, 130-180)
Lactate 
(mmol/L)
Pre-treatment 64 32 1.4 45 204 68 117
Baseline (DAAs started) 91 31 1.5 65 271 82 117
Day 7 131 32 1.5 55 205 76 114
Day 15 (Hospital admission) 273 31 1.5 52 196 77 101
Day 18
(Anti-HCV treatment stopped)
401 31 1.5 53 202 120 100
Day 24 427 27 1.9 50 176 186 93 1.3
Day 30 524 23 2.4 50 184 143 101
A B
Fig. 1. Histology of case 1 and case 2. (A) Case 1: Fibrous septa (black arrow)
with a mild mixed inflammatory infiltrate and mild ductular reaction with
associated neutrophilic inflammation bordering a nodular area of regenerating
hepatocytes. Focal ductular (white arrow) and canalicular (arrowhead) cholesta-
sis, rosette formation (black circle) and scattered parenchymal inflammatory foci
are present. H&E, 100. (B) Case 2: Inflamed portal tract with interface activity
and ductular reaction. The parenchyma shows cholestasis. H&E, 100.
JOURNAL OF HEPATOLOGY542 cells/ll, HIV-1 RNA not detected for 5 years) on Atripla
(efavirenz, emtricitabine, and tenofovir). His pre-treatment HCV
RNA was 4.0  104 IU/ml.
He started treatment with sofosbuvir (400 mg daily),
ledipasvir (90 mg daily), and ribavirin (600 mg twice daily) in
July 2014. Baseline serum bilirubin was 91 lmol/L (5.3 mg/dl).
On day 15 he was admitted to hospital with worsening jaundice
(bilirubin 273 lmol/L; 16.0 mg/dl) and vomiting (Table 1). By day
18 his bilirubin had risen to 401 lmol/L (23.5 mg/dl) and
sofosbuvir/ledipasvir/ribavirin were discontinued, but his HIV
medication continued. There was no significant drop in haemo-
globin to suggest ribavirin-related haemolysis and his conjugated
bilirubin was 278 lmol/L. He was empirically treated for possible
sepsis with piperacillin-tazobactam, although there were no
clinical features of infection and blood cultures were negative.
There were no features of drug hyper-sensitivity or signs of the
systemic inflammatory response syndrome (SIRS). Ultrasound
and magnetic resonance cholangiopancreatography showed no
biliary dilatation or obstruction. Tests for HBV (HBsAg/HBc anti-
body), hepatitis A virus immunoglobulin (HAV IgM), hepatitis E
virus IgM, cytomegalovirus, Epstein-Barr virus, adenovirus and
herpes simplex virus (all by PCR) showed no evidence of infection
and HCV RNA was not detected (<15 IU/ml). Trough efavirenz
level was 2059 ng/ml. The eosinophil count remained in the
normal range throughout the period of hepatic decompensation.
Transjugular liver biopsy showed cirrhosis with mild chronic
hepatitis, cholestasis and an additional acute hepatitis with acute
parenchymal inflammation including eosinophils, hepatocellular
injury and regenerative rosette formation, in keeping with drug
induced liver injury (DILI) (Fig. 1A; Supplementary Fig. 1). There
was no pre-treatment liver biopsy available for comparison.
Despite cessation of the DAAs his clinical condition deterio-
rated (Fig. 2A). He developed a Klebsiella pneumonia and died
from multi-organ failure on day 38.
Case 2
A 36-year-old woman with HCV genotype 3 cirrhosis was treated
with pegylated-interferon and ribavirin in 2012 but decompen-
sated after 37 days (becoming jaundiced) and treatment was
discontinued. She was assessed for liver transplantation, but as
her synthetic function was improving and in light of concerns
regarding surgical risks (body mass index 40), a period of monitor-
ing was initiated with lifestyle interventions. Her co-morbidities
were polycystic ovarian syndrome (PCOS), hypothyroidism,
hypertension and immunoglobulin A nephropathy. There was no
history of alcohol use. Three months after stopping antiviralJournal of Hepatology 201therapy her viral load had risen to 6.7  103 IU/ml. Over the next
year her liver synthetic parameters slowly deteriorated (MELD
16, UKELD 55). She started therapy in August 2014, using
sofosbuvir (400 mg daily), daclatasvir (60 mg daily) and ribavirin
(600 mg twice daily).
The patient was diagnosed with PCOS in 2010 and started
norethisterone (5 mg three times a day) for 3 weeks each month
until May 2014. At this time (75 days prior to starting the DAAs)
she was changed to the ‘mini-pill’ (desogestrel 75 lg daily). How-
ever, norethisterone (5 mg twice daily) was re-introduced in July
2014 for 4 weeks and then changed to Rigevidon (levonorgestrel
150 lg/ethinylestradiol 30 lg daily) on July 31st 2014 (11 days
prior to starting anti-HCV therapy). Her only other medication
was levothyroxine (150 lg daily). A previous liver biopsy in
2011 showed typical features of HCV cirrhosis (Ishak stage 6
and grade 6) with no striking presence of plasma cells.
At the start of the anti-HCV therapy the patient’s MELD and
UKELD scores were 16 and 55, respectively, with a bilirubin of
93 lmol/L. Within three weeks of starting DAA therapy there
was a marked worsening in her liver synthetic status (MELD 24,
bilirubin 313 lmol/L (18.3 mg/dl)) (Fig. 2B). A liver screen was
performed which was normal apart from a raised IgG (29.1;
elevated since 2011) and positive low titre anti-smooth muscle
antibody (present since 2012). Tests for HBV (HBsAg/HBc
antibody), HAV IgM, hepatitis E virus IgM, cytomegalovirus,
adenovirus and Epstein-Barr virus (all by PCR) were all negative.
Eosinophil levels were between 0.07–0.25 from starting the DAAs
to the time of transplantation. There were no physical signs of
drug hyper-sensitivity or SIRS.6 vol. 64 j 234–238 235
Liver biopsy
(22 days)
DAAs stopped
(18 days)
Hospital admission 
with jaundice
(15 days)
40
35
30
25
20
15
10
5
0M
od
el
 fo
r 
en
d-
st
ag
e 
liv
er
 d
is
ea
se
 (
M
E
LD
) 
sc
or
e
B
illirubin (µ m
ol/L)
Patient died
(38 days)
650
600
550
500
450
400
350
300
250
200
150
100
50
0
40
Number of days post anti-hepatitis C treatment initiation
35302520151050
Bilirubin
MELDA
B
Liver 
transplantation
(37 days)
Listed for liver 
transplantation
(31 days)
HCC treatment 
stopped
(24 days)
Liver biopsy
(22 days)
B
illirubin (µ m
ol/L)
500
450
400
350
300
250
200
150
100
50
0
40
Number of days post anti-hepatitis C treatment initiation
35302520151050 45 50 55M
od
el
 fo
r 
en
d-
st
ag
e 
liv
er
 d
is
ea
se
 (
M
E
LD
) 
sc
or
e
40
35
30
25
20
15
10
5
0
60
45
50
55
65
70
Bilirubin
MELD
Fig. 2. MELD/bilirubin profiles. (A) MELD/bilirubin profiles over a 38-day period
from starting oral anti-hepatitis C triple therapy, with highlighted important
clinical events. (B) MELD/bilirubin profiles over a 52-day period from starting oral
anti-hepatitis C triple therapy, with highlighted important clinical events.
Case ReportAfter 22 days, an ultrasound guided percutaneous liver biopsy
revealed plasma cell-rich inflammatory infiltrate with cholesta-
sis, in keeping with a drug reaction (Fig. 1B; Supplementary
Fig. 2). Antiviral therapy was stopped but she continued to dete-
riorate and was listed for liver transplantation 31 days after start-
ing the DAAs. Her bilirubin peaked at 499 lmol/L (29.2 mg/dl)
[day 34] (Table 2), and she underwent liver transplantation on
day 37. She is currently recovering from surgery with satisfactory
graft function and an undetectable viral load. The liver explant
showed similar features to the pre-transplant liver biopsy with
an acute hepatocellular injury on a background of HCV cirrhosis.
There was widespread cholestasis in all the regenerating nodules
and active inflammation including lymphoplasma cells and eosi-
nophils. There was evidence of recent hepatocyte loss, especially
at the edges of the regenerating nodules, with reticulin collapse
and ductular reaction. The explant also showed two high grade
dysplastic hepatocellular nodules but no convincing HCC.236 Journal of Hepatology 201This report describes the first experience of serious drug-
associated hepatotoxicity with the new DAAs. DILI is uncommon,
affecting between 1 in 10,000 to 19 in 100,000 people [5]. The
mechanism underlying these drug reactions is currently
unknown. They may represent idiosyncratic (Type B) drug reac-
tions which are rare and unpredictable [6]. According to the core
safety information for sofosbuvir, ledipasvir and daclatasvir no
dose adjustment is required in those with hepatic impairment
(irrespective of Child-Pugh score) [7,8]. However, few patients
with decompensated cirrhosis have had treatment with DAAs,
so the exact pharmacokinetics in this population have not been
characterised. The common factor in these cases was treatment
with sofosbuvir (NS5B inhibitor), an NS5A inhibitor and ribavirin.
Given the timing of events it is probable that the acute liver
injury was drug-related. Sofosbuvir is rapidly absorbed and
undergoes extensive first-pass hepatic metabolism. The
predominant circulating metabolite, GS-331007, is formed by
dephosphorylation of nucleotide metabolites, accounts for
approximately 78% of total systemic exposure and is principally
excreted in urine [8]. In advanced liver disease, the metabolism
of sofosbuvir may be altered leading to toxic liver injury. Alterna-
tively, genetic factors could play a role as shown with other
drugs, i.e. HLA-B⁄5701 allele carriers are at much greater risk of
DILI with flucloxacillin [9]. Further work is needed to establish
the underlying mechanism.
Ledipasvir and daclatasvir are both NS5A inhibitors and are
also potential candidates for the observed hepatotoxicity.
Ledipasvir can increase intestinal absorption of substrates for
the drug transporter P-glycoprotein and breast cancer resistance
protein (BCRP) [8]. Due to the high protein binding of ledipasvir,
clinically relevant transport inhibition is not expected [8]. While
sofosbuvir and ledipasvir are substrates for P-glycoprotein and
BCRP, GS-331007 is not. Ledipasvir is subject to slow oxidative
metabolism via an unknown mechanism and biliary excretion
is a major route of elimination. Daclatasvir is eliminated by hep-
atic metabolism and direct biliary excretion [10] with 88% being
excreted in faeces [7]. Biliary excretion of these drugs could be
impaired in the setting of advanced liver disease or secondary
to a bile transporter defect. This potential mechanism needs fur-
ther evaluation. In both cases, patients were taking or had
recently taken other drugs, which could have contributed to the
hepatotoxicity through an unknown interaction or reaction to
the drug. The first patient was taking Atripla with sofosbuvir/
ledipasvir. The core data sheet [11] shows no relevant drug inter-
actions between these drugs. However, the pharmacokinetics of
these drugs were tested in healthy volunteers, rather than
patients with advanced liver disease. Efavirenz can be hepatotox-
ic, but this patient had taken it for several years and levels were
within the therapeutic range.
Sofosbuvir/ledipasvir also interacts with tenofovir although
the risk is greater when a pharmacokinetic enhancer (e.g. riton-
avir) or a boosted protease inhibitor (e.g. darunavir) is also used
which was not the case here. When sofosbuvir/ledipasvir are
given in conjunction with Atripla, the maximum concentration
of tenofovir is increased to 1.79 (mean ratio) [90% CI 1.56–2.04]
[11]. The risk primarily relates to renal impairment which was
not a predominant problem in the case described. However, in
patients on anti-retroviral therapy for HIV this interaction must
be considered and tenofovir levels should be monitored. The sec-
ond patient was taking sofosbuvir/daclatasvir and had received
various oestrogen and progesterone-like compounds prior to6 vol. 64 j 234–238
Table 2. Routine blood results for case 2 during a period of hepatic decompensation.
Number of days post starting anti-
HCV therapy
Bilirubin 
(μmol/L, 2-21)
Albumin
(g/L, 35-50)
INR ALT
(IU/L, 0-40)
ALP
(IU/L, 70-300)
Creatinine 
(μmol/L, 64-104)
Haemoglobin 
(g/L, 135-180)
Pre-treatment 43 29 1.1 119 372 129
Baseline (DAAs started) 93 32 1.1 77 395 104 123
Day 11 151 32 1.2 71 398 106 119
Day 21 (Hospital admission) 313 31 1.3 89 373 127 109
Day 22
(DAAs stopped)
315 30 1.3 89 352 106 107
Day 25 342 25 1.5 71 358 117 95
Day 30 (Listed for transplant) 522 27 1.4 96 378 124 110
Day 34 499 26 1.3 184 366 140 103
Day 37 (Liver transplant) 490 27 1.4 137 311 129 93
Day 44 59 26 0.9 230 720 100 96
JOURNAL OF HEPATOLOGYtaking the DAAs. Liver-related complications are recognised with
oestrogens and oral contraceptives [12]. Oestrogens (estradiol
17b-D-glucuronide (E217G) or the synthetic oestrogen,
ethinylestradiol) can cause cholestasis due to changes in hepatic
bile acid transport protein expression [13] which results in inhi-
bition of the bile salt export pump on the luminal side of the
canalicular membrane [14]. Newer preparations have lower
doses of ethinylestradiol (15-35 lg) and more modern progestins
(e.g. desogestrel) are associated with lower rates of adverse side
effects [15]. To date, there has been no reported interaction
between these DAAs and hormonal treatments. However, inter-
estingly 26% of women taking concomitant ethinylestradiol-
containing medicines with dasabuvir (NS5B inhibitor) and
ombitasvir (NS5A inhibitor)/paritaprevir (protease inhibitor)/
ritonavir ± ribavirin experienced serum alanine aminotransferase
levels greater than 5 times the upper limit of normal after start-
ing treatment [16]. This highlights the potential for hepatotoxic-
ity in patients taking DAAs with oestrogens. Careful consideration
should be given to the use of oestrogens in patients with decom-
pensated liver disease, and should generally be avoided. Histolog-
ically, oestrogens classically cause a mild bland cholestasis,
which is different to the histological appearances (plasma cell
infiltrate) that were seen in the second case, suggesting that
the cholestasis seen was not purely oestrogen-related. The pres-
ence of eosinophils in the pre-transplant liver biopsy and explant
are important markers suggesting DILI.
Sepsis is a well-recognised cause of cholestasis and the first
patient was treated empirically with antibiotics. However, there
were no other clinical or histological features to support sepsis
as the cause of cholestasis in this case. Ribavirin was included
in the treatment algorithm for both patients. There are few stud-
ies of patients with such advanced liver disease receiving rib-
avirin and it is possible that this agent could be hepatotoxic in
patients with advanced cirrhosis. Neither patient suffered a sig-
nificant drop in haemoglobin that would suggest ribavirin-
related haemolysis.
In conclusion, we report two cases of severe DILI in patients
with decompensated hepatitis C cirrhosis treated with sofosbu-
vir, an NS5A inhibitor and ribavirin. While the association with
the DAAs is not proven, these cases highlight that patients with
advanced liver disease need close monitoring while on DAA ther-
apy and caution should be exercised with complex drug regi-
mens. If there is a significant unexplained deterioration in liver
function the DAAs should be discontinued.Journal of Hepatology 201Conflict of interest
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